Age-related hearing loss (ARHL), like neurodegenerative diseases, appears insidiously with age. As major public health issues, they are nonetheless under-diagnosed because the presence of one can hinder the objectification of the other. The CogAudio project aims to detect early and in an ambulatory mode in a memory centre a speech perception disorder in noise thanks to the VRB test in patients weakened by cognitive disorders.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
SCREENING
Masking
NONE
Enrollment
200
V1 (inclusion) : VRB test for detecting speech comprehension disorders in noise. V2 (3 months) : all patients ( independent of the result of the VRB test) will be invited to attend a hearing test within 3 months in order to confirm the diagnosis of deafness by means of a tone audiometry and an ENT medical consultation.
Hôpital Roger Salengro
Lille, France
RECRUITINGAbility of the VRB test to detect deafness in patients over 50 with mild to moderate cognitive impairment.
Area under the ROC (receiver operating characteristic) curve of the VRB test for hearing loss screening.
Time frame: 3 months
To assess the diagnostic values of the VRB threshold associated with a disorder of speech comprehension in noise defined in the general population to screen for deafness in patients over 50 years of age with mild to moderate cognitive impairment.
Sensitivity, specificity, negative and positive predictive values of the pathological threshold defined in the general population (\>3 BSR ) for hearing loss screening (as defined in the primary endpoint)
Time frame: 3 months or 12 months
correlation between the hearing loss and the auditory discomfort (complaint) expressed by the patient and that observed by the caregiver
Hearing loss is defined by the VRB test score. The auditory complaint expressed by the patient is defined by the score on the HHIE-S questionnaire completed by the patient himself; the auditory complaint noted by the entourage is defined by the score on the adapted HHIE-S questionnaire completed by the caregiver present at the consultation at M0.
Time frame: 3 months or 12 months
Frequency of patients with hearing aids at 12 months.
Frequency of patients with hearing aids at 12 months from inclusion
Time frame: 3 months or 12 months
Evolution of the cognitive and functional profile at 12 months between patients with deafness and patients without deafness.
Variation in scores between M0 and M12 on HAD neuropsychological and speech therapy test.
Time frame: 3 months or 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
To assess the correlation between an objective cortical marker of selective attention (long latency evoked potentials: P300 wave amplitude; patients' ability to discriminate sounds in silence), and subjects' performance in tone audiometry in silence
Amplitude and latency of the P300 wave; Tone audiometry score in silence.
Time frame: 3 months or 12 months
Evolution of the cognitive and functional profile at 12 months between patients with deafness and patients without deafness.
Variation in scores between M0 and M12 on WHOQOL-BREF neuropsychological test
Time frame: 3 months or 12 months
Evolution of the cognitive and functional profile at 12 months between patients with deafness and patients without deafness.
Variation in scores between M0 and M12 on QFS functional scale
Time frame: 3 months or 12 months
Evolution of the cognitive and functional profile at 12 months between patients with deafness and patients without deafness.
Variation in scores between M0 and M12 on LARS neuropsychological test.
Time frame: 3 months or 12 months
Evolution of the cognitive and functional profile at 12 months between patients with deafness and patients without deafness.
Variation in scores between M0 and M12 on EQ-5D-3L neuropsychological test.
Time frame: 3 months or 12 months